Top Markets
Coin of the day
Poolbeg Pharma PLC Poolbeg Pharma PLC

Poolbeg Pharma PLC

POLB
Rankning i aktier #38628
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the... Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Aktiekurs
$0.11565963
Marknadsvärde
$882.99K
Förändring (1 dag)
-2.30%
Förändring (1 år)
189.81%
Land
GB
Handel Poolbeg Pharma PLC (POLB)

Kategori

Utdelningsavkastning för Poolbeg Pharma PLC (POLB)
Utdelningsavkastningen (TTM) för Poolbeg Pharma PLC (aktiesymbol: POLB) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Poolbeg Pharma PLC (POLB) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter